Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | DRD4 | P21917 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2980930 | 0.92 | DRD2 (0.67) | DRD2DRD4ACHECXCR4 | |
| SCHEMBL2085442 | 0.86 | SMN1; SMN2 (0.56) | DRD2DRD4SMN1; SMN2RECQLACHE | |
| SCHEMBL8446486 | 0.85 | LTA4H (0.65) | DRD2DRD4ACHECXCR4 | |
| SCHEMBL15054621 | 0.83 | DRD2 (0.56) | DRD2DRD4CXCR4 | |
| SCHEMBL14127744 | 0.83 | DRD2 (0.56) | DRD2DRD4CXCR4 | |
| SCHEMBL28534937 | 0.82 | DRD2 (0.62) | DRD2DRD4ACHECXCR4 | |
| SCHEMBL7596783 | 0.81 | ACHE (0.54) | DRD2DRD4ALDH1A1KDM4ECHRM4 | |
| SCHEMBL28534938 | 0.80 | DRD2 (0.61) | DRD2DRD4ACHECXCR4 | |
| SCHEMBL8809184 | 0.80 | DRD2 (0.61) | DRD2DRD4ACHECXCR4 | |
| SCHEMBL31050638 | 0.79 | DRD2 (0.51) | DRD2DRD4KDM4EACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192729-A1 | Carboxylic acids and the esters thereof, pharmaceutical compositions thereto and processes for the preparation thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192729-A1 | Carboxylic acids and the esters thereof, pharmaceutical compositions thereto and processes for the preparation thereof | NPY1R, ADCY1, SRD5A1 | DRD2 368/4885DRD4 225/4885ALDH1A1 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.